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Abstract
This  chapter  focuses  on  recent  applications  of  flow  hydrogenation  in  medicinal
chemistry. Flow reactors can enhance laboratory safety, reducing the risks associated
with pyrophoric catalysts, due to their containment in catalyst cartridges or omnifit
columns. Flow hydrogenation reduces the risks arising from hydrogen gas, with either
hydrogen generated in situ from water, or precise management of the gas flow rate
through  tube-in-tube  reactors.  There  is  an  increasing  body  of  evidence  that  flow
hydrogenation enhances reduction outcomes across nitro, imine, nitrile, amide, azide,
and  azo  reductions,  together  with  de-aromatisation  and  hydrodehalogenation.  In
addition, olefin, alkyne, carbonyl, and benzyl reductions have been widely examined.
Further, protocols involving multistage flow reactions involving hydrogenation are
highlighted.
Keywords: hydrogenations, flow technologies, flow synthesis, reduction, multistage,
flow hydrogenation, chemoselective, catalyst
1. Introduction
In 2013, 25% of marketed drugs required at least one hydrogenation step in their production
[1, 2]. Hydrogenation mediated manipulation of nitro, imine, nitrile, amide, azide, and azo
moieties,  as well  as de-aromatisation, hydrodehalogenation, olefin, alkyne, carbonyl,  and
benzyl reductions are fundamental to drug discovery and development programmes [1, 3].
Flow hydrogenation offers the benefits of improved safety, yield, selectivity and reduced
purification over traditional hydrogenation approaches. Flow hydrogenation through the use
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of contained pyrophoric catalysts, replacement of hydrogen reservoirs with in situ hydrogen
generation, improved temperature control, and smaller solvent volumes all contribute to an
increase in hydrogenation safety [4]. Flow technologies have improved hydrogenation
outcomes by increasing substrate-gas-catalyst interactions and permitting stringent control of
reaction parameters (temperature, flow rate, and pressure) with a commensurate reduction in
undesirable side product and improved selectivity. Combined with optimised reaction
conditions, this generally means very little or no further purification is required after the
reaction [1].
This chapter details key recent development in functional group transformation, multistep
synthesis utilising flow hydrogenation and technology advances [1, 3].
2. Instrumentation
Unlike batch reactions where gas-solvent contact is limited by diffusion of gas into the bulk
solvent, flow hydrogenation rapidly saturates the solvent with hydrogen using two different
approaches [5]. The first, used by the ThalesNano H-cube®, employs in-line mixing of hydro-
gen with the solvent under pressure, which prevents outgassing and rapid solvent stream
saturation (Figure 1A) [6]. The second approach, used by the Vapourtec Gas/Liquid reactor
(Figure 1B) and Gastropod Gas Liquid Module, employs gas permeable membranes in a tube-
in-tube reactor. These systems enable solvent stream saturation by passing hydrogen gas under
pressure through a gas porous polymer and into the solvent [7–10].
Figure 1. Schematic of the mechanical mixing setup in (A) the ThalesNano H-Cube® and (B) schematic of the gas per-
meable membrane (tube-in-tube) technology [1].
The Thalesnano H-cube® was the first commercial flow hydrogenator. Together with the use
of in-line gas mixing, the H-cube uses exchangeable 30 or 70 mm heterogeneous catalyst
cartridges and a HPLC pump. Hydrogen gas is generated in situ through water electrolysis.
The system is capable of heating to 100°C and 150 bar, with a flow rate range from 0.5 to 5.0
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mL min−1 [11]. Tube-in-tube reactors require specialised materials displaying high gas perme-
ability while being impermeable to (nonfluorinated) liquids and corrosive chemicals, e.g.,
Teflon AF-2400 [12]. The Vapourtec Gas/Liquid system uses ‘plug-in reactors’ and the Gastro-
pod Gas Liquid Module can be equipped with a small gas cylinder or attached to any custom
flow systems [9, 10].
3. Functional group transformations
3.1. Nitro reductions
Flow nitro reductions, using palladium, platinum, and Raney Ni catalysts, under optimised
conditions have been shown to provide both increased yield and simplified work up [1, 3].
Abdel-Hamid et al’s recent synthesis of 1,8-naphthalimide derivatives illustrates this with an
increase in yield (86–98%) and purification simplification (chromatographic to extractive)
(Figure 2) [13].
Figure 2. Synthesis of 1,8-naphthalimide derivatives. Reagents and conditions: (i) ThalesNano H-Cube®, 10% Pd/C,
THF, 40°C, 10 bar, 1 mL min−1, 2 cycles; (ii) SnCl2, HCl, ethanol, reflux 2 h; (iii) (a) fuming sulfuric acid, 50°C, 3 h; (b)
saturated aq. KCl, room temperature.
The utility of the flow nitro reduction extends across pyrrolidine, carboxylate ester, phenyl
propanoate, benzothiopene, benzofurans, and indole-carboxylate scaffolds. These reactions
employed either Raney Ni or 10% Pd/C catalysts from 25 to 65°C and atmospheric (atm)—20
bar, respectively, providing excellent reaction outcomes (Table 1).
3.2. Alkene reductions
Flow hydrogenation is particularly useful in the reduction in alkene and alkyne bonds as is
evident from the examples shown in Table 2. Gericke et al. developed ruthenium-nitrogen-
doped carbon nanotubes (NCNT) and ruthenium-hyperbranched polystyrene-supported
(HPS) catalysts, providing a more sustainable process [24]. Gericke et al. suggested that HPS-
and NCNT-supported catalysts are a suitable alternative to Raney Ni and have an increased
production rate per mole of catalyst compared to Raney Ni. Multiple similar alkene and alkyne
reductions have been reported (Table 2). These hydrogenation catalysts were found not to be
limited to the hydrogenation of alkenes and alkynes and have been applied in the reduction
in glucose 4 to sorbitol 5, which traditionally has relied on expensive catalysts such as Raney
Ni (Figure 3).
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Starting material Product Yield Catalyst Conditions References
90% Ra-Ni 65°C, 20 bar, 1.0 mL min−1 [14]
100% 10% Pd/C 25°C, 1–30 bar [15]
100% 10% Pd/C 50°C, 1 bar, 1.0 mL min−1 [16]
88–98% 10% Pd/C 40–60°C, 1 bar, 0.5–1.0 mL min−1 [17]
Table 1. Flow nitro reduction of selected analogues.
Starting material Product Yield Catalyst Conditions References
86% 10%
Pd/C
25°C, 10 bar,
recirculate 2 h
[18]
21% 5%
Rh/C
70°C, 1 bar,
1.5 mL min−1, 3 cycles
[19]
98% 10%
Pd/C
40°C,
1 mL min−1
[20]
84% 10%
Pd/C
30°C, 40 bar,
1 mL min−1, 2 cycles
[21]
99% RaNi 60°C, 60 bar,
1 mL min−1, 24 h
[22]
Quant. 10%
Pd/C
50°C, 1 bar [23]
Table 2. Flow reduction of selected alkenes and alkynes.
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Figure 3. Reaction scheme for the hydrogenation of D-glucose (4).
Initial attempts by Yadav et al. under batch reaction conditions to access alcohol 6 afforded an
8:2 mixture of 6 and ketone 7 [20]. The use of the H-cube® and relatively mild reducing
conditions (10% Pd/C, 40°C, and 6 bar) gave exclusively 6 in a near-quantitative yield
(Figure 4).
Figure 4. Synthesis of the marine macrolide sanctolide 6 via batch and flow hydrogenation. Reagents and conditions:
(i) H2, Pd/C (10%), EtOAc, rt, 8 h; (ii) H-cube®, Pd/C (10%), MeOH, 40°C, 6 bar.
Trobe and Breinbauer highlighted the use of flow methodologies to improve reaction yields
(Figure 5) [22]. The trifluoroether 11 was accessed through a conventional traditional Witting/
hydrogenation approach in a 32% yield. A modified access via a Claisen rearrangement and
flow hydrogenation was developed leading to 11 in a 71% yield.
Figure 5. Improving the yield of a synthetic route from 32% to 71% with the aid of flow hydrogenation. Reagents and
conditions: (i) salicylaldehyde, toluene, 80°C, 8 h; (ii) H2, Pd/C, MeOH, 22°C, 3 h; (iii) DMAc, 190°C, 5 d; (iv) H-cube®,
Ra-Ni, 60°C, 60 bar; (v) (i) ICl, AcOH, 22°C, 24 h; (ii) Tf2O, pyridine, 0°C, 2 h.
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3.3. Reductive amination
Traditionally, borohydride reagents such as NaCNBH3, NaBH(OAc)3, or pyridine-BH3 have
been used for reductive amination [25]. However, flow hydrogenation offers considerable
advantages over transfer hydrogenation, such as improved atom economy, reduced environ-
mental impact, simple reaction workups, and reduced exposure to toxic or reactive starting
materials [26].
Flow reductive aminations are generally conducted using 10% Pd/C or 20% Pd(OH)2/C, with
the temperatures and pressures used substrate-dependent [1]. However, the use of an Au/
Al2O3 catalyst has facilitated a cascade nitro reduction and direct reductive amination to afford
secondary amine 16 (Figure 6). Unlike many conventional Pd- and Ni-based catalysts, the
Au/Al2O3 catalyst showed selective reduction in the nitrobenzene 14 over benzaldehyde 15,
aiding imine formation and subsequent reductive amination. Under optimised conditions
(1:1.5 nitrobenzene 14: benzaldehyde 15, 80°C and 50 bar), the desired N-benzylaniline 16 was
generated in a 91% yield (Figure 6) [27].
Figure 6. Flow reductive amination to afford N-benzylaniline 16. Reagents and conditions: H-cube® Pro, 0.05 M 15 in
EtOH, Au/Al2O3 (70 mm), 125°C, 10 bar, 0.3 mL min−1.
Treatment of phenethylamine (18) and levulinic acid (17) in 2-methylfuran under the hydro-
genation conditions of 85 bar H2 pressure, 150°C and carbon-supported Fe/Ni yielded
pyrrolidine 19 with a 91% conversion via a sequential reductive amination and cyclisation
process (Figure 7) [28].
Figure 7. Flow reductive amination with carbon-supported Fe/Ni (C-Fe/Ni) to form pyrrolidine 19. Reagents and con-
ditions: H-cube® Pro, 0.025 M 18 in 2-methylfuran, C-Fe/Ni alloy (70 mm), 150°C, 85 bar, 0.3 mL min−1.
3.4. Protecting group manipulation
The synthesis of carbohydrate and nucleoside mimics has led to the development of C-
nucleosides and C-glycosides as antibiotic, anticancer, and antiviral agents [29]. Using flow
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chemistry, Redpath et al. were able to access the deprotected 2-deoxy-C-galac-topyranosyl-
benzoic acid 26 (Figure 8) [29]. The final stage of the multistep reaction, including the hydro-
genation, provided 26 in a 39% yield over five steps. This route was found to provide access
to galactoside and mannoside type C-nucleosides incorporating functionality analogous to the
biologically important benzamide riboside through the use of an oxazoline protecting group,
which had been previously inaccessible using a transmetallation/inter molecular Sakura
condensation approach.
Figure 8. Synthesis of (D/L)-deoxy-β-galactopyranosyl-benzoic acid (26). Reagents and conditions: (i) SOCl2, toluene;
(ii) H2NC(CH3)2CH2OH, CH2Cl2; (iii) sec-BuLi, TMEDA, Et2O; (iv) Ti(OiPr)4; (v) crotonaldehyde, BF3·OEt2, CH2Cl2; (vi)
MsCl, Net3, CH2Cl2; (vii) O3, CH2Cl2/MeOH then Me2S; (viii) NaBH4; (ix) LiAlH4, THF; (x) BnBr, TBAI, NaH, 15-
crown-5, THF; (xi) MeI, MeNO2; (xii) 20% KOH, MeOH; (xiii) H2, 10% Pd/C, MeOH.
Pd-catalysts and mild (RT, 1 bar) to moderate (45°C, 10 bar) conditions have been employed
for the removal of benzyloxy carbamate (CBz) and benzyl (Bn) protecting groups (Table 3).
3.5. Multistep synthesis
A number of integrated multistep flow syntheses, with hydrogenation a key step, have been
reported and are typically characterised by the reduced need for purification between synthetic
steps.
Previous batch syntheses of the kinase inhibitors CTx-0152960 and CTx-029488 required the
use of Boc-piperidine in the key SNAr coupling with 1-fluoro-4-nitrobenzene to prevent
formation of unwanted side products. Flow approaches removed this requirement facilitating
rapid access to the Boc-free analogues in high yields (Figure 9) [33]. Of note, the flow hydro-
genation of both the SNAr adducts of piperidine and morpholine (27) required no purification.
Microwave coupling of 4-morphilinoaniline and 4-(piperazine-1-yl)aniline with 2-(2,5-
dichloropyrimidine-4-ylamino)-N-methylbenzamide afforded access to the desired 31a and
31b. This hybrid approach reduced the number of synthetic steps, enhanced product yield,
and increased atom economy through step reduction and minimal requirement for chroma-
tographic purification, relative to the original batch approach [33].
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Starting material Product References
[30]
CBz protecting group 20% Pd(OH)2/C; 45°C, 10 bar, 1.0 mL min−1, 1 cycle;
67%
[31]
Benzyl protecting group 10% Pd/C; 65°C, full H2 mode, 1.0 mL min−1, 1 cycle;
60%
[32]
Benzoyl protecting group
[56]
Phthalimide protecting group 10% Pd/C; 50°C, 1 bar, 50°C, 0.5 mL min-1; 56–81%
[57]
Cbz protecting group 10% Pd/C; RT, 1 bar, 50°C, 1.0 mL min−1; 99%; 97% ee
Table 3. Flow reduction and removal of protecting groups.
The modular nature of flow chemistry instrumentation has allowed Ghislieri et al. by simple
manipulation of the module order and selection of staring material to produce five active
pharmaceutical ingredients (APIs) across three structural classes (γ-amino acids, γ-lactams,
β-amino acids). From benzyl alcohol eight compounds of interest including the drugs Lyrica
and Gabapentin were synthesised in good overall yields (49–75%) (Figure 10) [34].
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Figure 9. Synthesis of broad kinase inhibitors 31a and 31b by multistep flow synthesis. Reagents and conditions: (i)
Vapourtec R2+, 4M piperidine or morpholine in DMF, 2 M 1-fluoro-2-nitrobenzene in DMF, 8 bar, 5 mL min−1; (ii) H-
CubePro, 0.05M in MeOH, 10% Pd/C CatCart® (70 mm), 50 bar, 50°C, 1.0 mL min−1; (iii) Syrris FRX-100, 40% w/w aq.
MeNH2, 0.5 mL min−1, 0–19°C, 19 h; (iv) Vapourtec R2+, 2,3,5-tri-chloropyrimidine, iPrNEt, iPrOH, 4 bar 100°C; (v) n-
BuOH, 4 M HCl in dioxane (cat), 150°C, μW, 20 min.
Figure 10. Divergent multistep flow synthesis of γ-amino acid derivatives. Reagents and conditions: (i) bleach (2.5 eq.),
TEMPO (0.05 eq.), NaHCO3 (0.3 eq.), KBr (0.2 eq.), 0°C; (ii) triethylphosphonoacetate (1.1 eq.), tBuOK (1.1 eq.), 50°C;
(iii) CH3NO2 (11 eq.), TBAF (1.3 eq.), 50°C; (iv) H-cube®, Pd/C (10%), 60°C, 60 bar; (v) LiOH (3 eq.), 50°C. LLS = liquid-
liquid separator. Yields for individual modules determined upon isolation.
The flow chemistry modules above have also been used for the efficient synthesis of a number
of known APIs (Figure 11). Within this multistage process, module five employed the use of
the H-cube for the preparation of β-amino acids from unsaturated α-nitrile ester (90 bar, 100°C,
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Raney Ni). For nitro reductions, Pd/C and Raney Ni catalysts were favoured and afforded the
desired compounds in good-to-excellent yields.
Figure 11. APIs prepared via the convergent multistep synthesis exemplified in Figure 10. Yields are reported for full
processes without immediate purification over the 3–5 steps.
Both (R)- and (S)-rolipram were generated by using flow approaches and required no isolation
of intermediates or purification, a significant step towards the automated manufacture of
APIs [35]. The overall process used is outlined in Figure 12. While commercially available Ni
and Pd catalysts failed in the case of aliphatic nitro compounds, however, a newly developed
dimethylpolysilane-supported palladium/carbon (Pd/DMPSi-C) catalyst afforded the desired
δ-lactam in a 74% yield (94% ee).
Figure 12. (A) Multistep flow synthesis of (S)-rolipram. Reagents and conditions: (i) Si-NH2/CaCl2, toluene, 75°C, 50 μL
min−1; (ii) PS-(S)-Pybox, CaCl2·2H2O, 0°C, 100 μL min−1 (total); (iii) Pd/(DMPSi-C) (1.6 mmol), 100°C, 100 μL min−1 (to-
tal); (iv) HOOC-silica gel, 120°C, 210 μL min−1 (total). The flow reaction was continued for a week and the yield and the
enantioselectivity maintained. (B) Further details of the flow hydrogenation step.
The success of multistage flow synthesis in API production, especially the use of flow hy-
drogenation suggests that these approaches will continue to rapidly develop and potentially
become a standard method of synthesis.
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3.6. Scaffold formation
Flow hydrogenation has provided access to scaffolds that were inaccessible via batch hydro-
genation pathways such as the 1,4-benzodiazepin-5-ones (Figure 13). This scaffold has been
targeted in treatments for tuberculosis [36] and control of the melanocortin receptors impli-
cated in appetite control [37] and was readily accessed under flow conditions (THF, 0.3 mL
min−1, 50 bar and 80°C). Isolated yields of up to 94% (45) requiring no purifications were noted
[38].
Figure 13. Synthesis of the desired 1,4-benzodiazepin-5-ones 43 via batch and flow hydrogenation. Reagents and con-
ditions: (i) H2, Pd/C (10%, 0.1 eq.), EtOAc:EtOH, 2:1 (0.03 M), 20°C, 1 atm; (ii) 1,4-cyclohexadiene (6 eq.), microwave
mode, Pd/C (10%, 0.05 eq.), MeOH (0.1 M), 120°C; (iii) H2, Ru/C (5%, 0.02 eq.), THF (0.03 M), 20°C, 1 atm; (iv) H2, Ru/C
(5%, 0.02 eq.), THF (0.03 M), reflux, 1 atm; (v)) H2, Ru/C (5%, 0.04 eq.), THF (0.03 M), 20°C, 1 atm; (vi) FeSO4·7H2O (10
eq.), NH4OH, EtOH, reflux; (vii) Fe (20 eq.), AcOH (0.1 M), 70°C; (viii) H-cube Pro®, Ru/C (5%), THF, 80°C, 50 bar, 0.3
mL min−1.
The chiral ester (45) is a key intermediate in the synthesis of the angiotensin II receptor blocker
sacubitril. Enantioselective flow hydrogenation using a tube-in-tube system, through two
loops, provided access to the required diastereomer at 0.45 g h−1. The introduction of the second
loop was critical increasing the yield from 78 to 99% (Figure 14) [39].
Figure 14. Enantioselective hydrogenation flow preparation of chiral ester 45. Reagents and conditions: H2, cat. DIPEA
in EtOH (1 mol%), 20°C, 25 bar, 0.2 mL min−1.
In a similar manner, H-cube mediated nitro reduction and lactam cyclisation of γ-nitro-α-
amino esters with in situ cyclisation afforded, quantitatively, the corresponding γ-lactams (47)
(Figure 15). Raney Ni hydrogenation (10 bar, 65°C) of the syn- diastereomer affords exclusive-
ly the trans- configuration with the anti-γ-nitro-α-amino esters gave the cis diastereomer [40].
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Figure 15. Formation of γ-lactams via flow hydrogenation. Reagents and conditions: (i) H-cube®, Raney Ni, MeOH
(0.01 M), 65°C, 10 bar, 1.0 mL min−1.
3.7. Other reactions
A variety of other reductions that are pertinent to medicinal chemistry can also be performed
via flow hydrogenation as shown in Table 4.
Type of reaction Starting material Product Conditions References
Azide reduction 10% Pd/C, RT, 1 bar, 1.0 mL min−1, 94% [41]
Olefin reduction
  
10% Pd/C, 80°C, 60 bar, 2.0 mL min−1, 90% [42]
De-aromatisation 10% Ru/C or 10% Rh/C, 75–100°C, 50 bar, 1.0
mL min−1, 100%
[43]
Selective reduction 20% Pd/C, 100°C, 5 bar, 1.0 mL min−1, 58% [44]
Hydroformylation 
11 examples
Rh(CO)2(acac), 65°C, 25 bar, 0.6 mL min−1, 69–94%
[45]
Table 4. Selected other common flow reduction reactions.
In the synthesis of the antimalarial drug, OZ439 49, Lau et al. optimised the hydrogenation
step successfully reducing only one of the aromatic rings using 20% Pd/C (Figure 16) [44]. The
concentration of the undesired minor by-products 50 and 51 was minimised by control of the
temperature and the amount of hydrogen entering the system. This flow approach to 49 also
avoided the use of genotoxic 4-(2-chloroethyl)morpholine.
3.8. Deuteration
The incorporation of a deuterium label has been used widely to probe reaction mechanisms,
to probe a compound’s pharmacokinetic properties, and as an internal standard in NMR and
mass spectrometry [46]. The increase in bond strength (C-H versus C-D) can modify a drug’s
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pharmacokinetic profile, and this has led to the development of deuterium containing drugs.
Deutetrabenazine (SD-809) is expected to be the first deuterated drug approved by the FDA.
Figure 16. Selective continuous flow hydrogenation of 4-4′-biphenol 48. Reagents and conditions: (i) H2 (0.1 L min−1),
Pd/C (20%), EtOH/H2O (1:1 v/v, 0.05 M), 100°C, 5 bar, 1.0 mL min−1.
The synthesis of SD-809 is not flow mediated, but its success does suggest that the incorpora-
tion of deuterium will become a more common feature in future drugs [47]. Deuterium
incorporation can be accomplished from D2 gas and catalytic H-D exchange reactions be-
tween H2 and D2O. There are disadvantages to using deuterium gas on a laboratory scale, such
as the handling of the gas itself, and the catalytic approaches are time consuming and do not
always produce high purity D2. However, electrolysis of D2O by the Thales Nano H-cube®
offers direct and rapid access to high purity D2 gas and is applicable across the suite of
reduction chemistries discussed above affording highly flexible incorporation of deuterium.
Hsieh et al. have demonstrated this in the deuteration of a series of trans-chalcones (52) of
interest for their antidiabetic activity (Figure 17) [48].
Figure 17. Deuteration of trans-chalcone and various derivatives. Reagents and conditions: (i) H-cube®, D2O, 5% Pt/
Al2O3, 100°C, 100 bar, 1 mL min−1. Insert: chemical structure of SD-809.
Access to the required D2-gas uses two separate inlet streams where the sample is introduced
in an aprotic solvent and with D2O electrolysis providing the required gas at which point the
streams were combined and passaged over the deuteration catalyst (Figure 18).
Figure 18. Schematic outline of the continuous flow reactor used to prepare deuterated compounds by Hsieh et al [48].
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The C2-halogen played a significant role in determining the ratio of di- to tri-deuterated
species. With all analogues except the 2-F, conversions of ≥90% and exclusive formation of the
di-deuterated species (53) were observed with 5% Pt/Al2O3. However with (E)-1-(2-fluoro-
phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one this catalyst afforded a 5:95 ratio of 53:54 with
97% conversion. Switching to the less active Pd/BaSO4 catalyst afforded 100% conversion of
the 2-F analogue, with a best ratio of 89:11 (53:54). The presence of the fluorine had a significant
effect on the deuteration of this family of chalcones.
3.9. New catalysts
As further catalysts are developed for flow hydrogenation, the specificity and robustness of
the chemical transformations achievable increase. Flow hydrogenation does require the use of
a rare metal catalyst, which can be both expensive and potentially environmentally unsus-
tainable. This negates the toxicity and disposal problems related to classical reducing agents
and suggests that flow hydrogenation approaches may be expensive and not environmentally
benign. This has led to the development of alternative hydrogenation catalysts such as carbon-
supported iron-phenanthroline complexes, nickel nanoparticles, and FeNi alloys. These new
catalysts show broad spectrum reductive capabilities (Table 5).
Catalyst Starting material Product Conditions References
1.9% Au/Al2O3 Substitutednitrobenzenes (6examples)
Substitutedanilines (6 examples) 60–110°C, 10–20 bar, 0.5 mL min−1, 98–100% [49]
Pd/C (3%)Bimodal and trimodal Alkyne, aldehyde,and halogenated species Various 60–110°C, 1 bar, 0.5 mL min
−1,24–43 Selectivity 51–100% [50]
ARP-Pt Olefins (24 examples)and nitrobenzenes (9examples)
Olefin yield not reported; nitroreduction up to 99% [51]
25°C, 5 bar, 2.0 mL min−1, >99%
25°C, 15 bar, 1.5 mL min−1, >99%
Pd-Maghemite Substitutednitrobenzenes (13examples)
Substitutedanilines  30°C, 1 bar, 0.5 mL min
−1,86–98% [52]
30°C, 1 bar, 94%
30°C, 1 bar, 0.5 mL min−1, 88%
Designed porous structurereactor (DPSR)Al2O3-ZnO
60–80°C, 6 bar, 37 kg h−1, >99% [53]
Pd0-AmP-MCF(heterogeneous Pdnanocatalyst supported onaminofunctionalizedmesocellular foam)
Michael acceptors (14examples) Aldehydes andalcohols [54]
20°C, 1 bar, 1.5 mL min−1, 94%
Table 5. Use of novel catalysts in flow reduction reactions.
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Dehydrohalogenation is a significant and ongoing concern in flow (and batch) reduction [55],
and thus the development of new catalysts that specifically avoid this outcome is a valuable
research tool. Osako et al. used platinum nanoparticles dispersed on an amphiphilic polystyr-
ene-poly(ethylene glycol) (ART-Pt) resin as a catalyst was specifically developed to avoid
reduction of –Cl, −C=O, and –CN moieties, e.g., 55a-56c (Figure 19) [51].
Figure 19. Alkene reductions via flow hydrogenation using the ARP-Pt catalyst. Reagents and conditions: X-cube®, H2
(5 vol%), ARP-Pt (0.073 mmol Pt), EtOH (50 mM), 5 bar, 2mL min−1.
Specialist catalyst development has often been targeted towards chemoselectivity. Fan et al.
have shown that the Pd/triC catalyst was selectively reduced alkyne groups over nitro, bromo,
and aldehyde groups [50]. While Rathi’s palladium nanoparticles supported on maghemite
were effective in reducing nitroarenes, azides, and alkenes in good to excellent yields [52].
Nagendiran et al. detail the use of aminofunctionalised mesocellular foam-supported nano-
palladium in the conjugate reduction in a series of Michael acceptors [54]. Both the Vapourtec
(1.0 mL min−1, 0.1 M, 1 bar H2, 20°C) and the H-cube (1.0 mL min−1, 0.1 M, 40 psi H2, 50°C) with
this catalyst afforded chemoselective reduction in the olefin moiety. This approach was scalable
enabling the selective reduction of cinnamaldehyde to 3-phenylpropanal on an approximately
20 g scale with no observed loss of catalysts’ activity or selectivity.
4. Conclusions
The body of evidence continues to grow illustrating that flow methodologies, in particular
flow hydrogenation, offer significant advantages over batch technologies in medicinal
chemistry. Flow chemistry has been demonstrated to enhance yields, simplify reaction work
up, improve safety, and allow in-line analysis. The coupling of modular flow systems has
allowed automated and semiautomated high yield, low purification requirement synthesis of
active pharmaceutical ingredients over multiple cascading steps.
Flow-based reductions continue to provide greater access to new chemical scaffolds for use in
drug design and development as well as to provide efficient methods for the production of
current pharmaceuticals.
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